Novo Nordisk’s ultra-long-acting insulin degludec, an investigational basal insulin being developed, showed significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily up to 40 hours apart, according to data presented today at the European Association for the Study of Diabetes (EASD) in Lisbon.
The study showed that HbA1c levels at 26-weeks were reduced by 1.28 percentage points to 7.2% with insulin degludec, comparable to Sanofi’s Lantus (insulin glargine). Additionally, fasting plasma glucose (FPG) reductions were significantly lower for insulin degludec (5.8mmol/l) at the end of the study than for Lantus.
This study demonstrates that with insulin degludec glycemic control can be maintained even if people unintentionally delay a dose or take their insulin at a different time of the day,” said Professor Stephen Atkin, lead author of the study and Head of Academic Endocrinology, Diabetes and Metabolism, York Hull Medical School, UK. “This flexibility without compromising glucose control or the risk of hypoglycemia is unprecedented, and suggests that insulin degludec could potentially offer a real advance in diabetes management for patients who are challenged to maintain exactly the same schedule from day to day.”
Source: Novo Nordisk